Description
A long-acting GLP-1 receptor agonist (modified exendin-4 peptide) that stimulates insulin secretion, suppresses glucagon, and reduces appetite. Semaglutide is FDA-approved for type 2 diabetes and obesity (as Ozempic®/Wegovy®). Research in rodents (5 mg kit) shows it improves glycemic control and causes significant weight loss by inducing satiety and increasing energy expenditure. It also has cardiovascular benefits (e.g., reducing atherosclerosis in ApoE-/- mice).




Reviews
There are no reviews yet.